Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

AstraZeneca Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (112)
Cancellation by sponsor (74)
Prescription medicine registration (61)
Australian Public Assessment Report (AusPAR) (48)
Designation or determination (24)
Prescription medicine decision summary (12)
Prescription medicine evaluation (10)
Section 14, TGO91 consent (1)

Date

2026 (17)
2025 (36)
2024 (28)
2023 (30)
2022 (45)
2021 (25)
2020 (16)
2019 (20)
2018 (19)
2017 (14)
2016 (11)
2015 (14)
2014 (13)
2013 (6)
2012 (3)
2011 (5)
2010 (4)
2008 (3)
2006 (5)
2004 (2)
2003 (5)
2002 (2)
2001 (2)
1997 (2)
1996 (3)
1991 (12)

Search

Sponsor content

342 result(s) found, displaying 141 to 150

BYDUREON exenatide 2 mg powder for injection vial with diluent syringe Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VIBRENT rosuvastatin (as calcium) 20mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VIBRENT rosuvastatin (as calcium) 10mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
VIBRENT rosuvastatin (as calcium) 5mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
TALEXAR rosuvastatin (as calcium) 40mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
TALEXAR rosuvastatin (as calcium) 20mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AFFORA rosuvastatin (as calcium) 40mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AFFORA rosuvastatin (as calcium) 20mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

29 June 2022

Cancellation by sponsor

Requested by AstraZeneca Pty Ltd
AusPAR: Trastuzumab deruxtecan

27 June 2022

Australian Public Assessment Report (AusPAR)

Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.
Notice for trastuzumab deruxtecan (AstraZeneca Pty Ltd)

18 May 2022

Designation or determination

Priority review

Pages

First page
Previous page
…
Page 11
Page 12
Page 13
Page 14
Current page 15
Page 16
Page 17
Page 18
Page 19
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.